143 related articles for article (PubMed ID: 15756014)
21. A study of the effect of temperature on the pharmacokinetic profile of raltitrexed administered by intraperitoneal route in the rat.
Bendavid Y; Leblond FA; Dubé P
Med Sci Monit; 2005 Jan; 11(1):BR1-5. PubMed ID: 15614183
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
23. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Ricart AD; Berlin JD; Papadopoulos KP; Syed S; Drolet DW; Quaratino-Baker C; Horan J; Chick J; Vermeulen W; Tolcher AW; Rowinsky EK; Rothenberg ML
Clin Cancer Res; 2008 Dec; 14(23):7947-55. PubMed ID: 19047127
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Jodrell DI; Bowman A; Rye R; Byrne B; Boddy A; Rafi I; Taylor GA; Johnston A; Clendeninn NJ
Br J Cancer; 1999 Feb; 79(5-6):915-20. PubMed ID: 10070890
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Beutel G; Glen H; Schöffski P; Chick J; Gill S; Cassidy J; Twelves C
Clin Cancer Res; 2005 Aug; 11(15):5487-95. PubMed ID: 16061865
[TBL] [Abstract][Full Text] [Related]
27. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
[TBL] [Abstract][Full Text] [Related]
28. Clinical and preclinical pharmacokinetics of raltitrexed.
Clarke SJ; Beale PJ; Rivory LP
Clin Pharmacokinet; 2000 Dec; 39(6):429-43. PubMed ID: 11192475
[TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
[TBL] [Abstract][Full Text] [Related]
31. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
[TBL] [Abstract][Full Text] [Related]
32. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
[TBL] [Abstract][Full Text] [Related]
34. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Beale P; Judson I; Hanwell J; Berry C; Aherne W; Hickish T; Martin P; Walker M
Cancer Chemother Pharmacol; 1998; 42(1):71-6. PubMed ID: 9619761
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Doz F; Gentet JC; Pein F; Frappaz D; Chastagner P; Moretti S; Vassal G; Arditti J; Tellingen OV; Iliadis A; Catalin J
Br J Cancer; 2001 Mar; 84(5):604-10. PubMed ID: 11237379
[TBL] [Abstract][Full Text] [Related]
36. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
Clarke SJ; Hanwell J; de Boer M; Planting A; Verweij J; Walker M; Smith R; Jackman AL; Hughes LR; Harrap KR; Kennealey GT; Judson IR
J Clin Oncol; 1996 May; 14(5):1495-503. PubMed ID: 8622063
[TBL] [Abstract][Full Text] [Related]
38. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
Galetta D; Giotta F; Rosati G; Gebbia V; Manzione L; Di Bisceglie M; Borsellino N; Colucci G
Anticancer Res; 2005; 25(6C):4445-9. PubMed ID: 16334124
[TBL] [Abstract][Full Text] [Related]
39. Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck.
Clarke SJ; Zalcberg J; Olver I; Mitchell PL; Rischin D; Dalley D; Green M; Davidson YE
Ann Oncol; 2000 Feb; 11(2):239-41. PubMed ID: 10761765
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
Gururangan S; Turner CD; Stewart CF; O'Shaughnessy M; Kocak M; Poussaint TY; Phillips PC; Goldman S; Packer R; Pollack IF; Blaney SM; Karsten V; Gerson SL; Boyett JM; Friedman HS; Kun LE
Clin Cancer Res; 2008 Feb; 14(4):1124-30. PubMed ID: 18281546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
